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ABSTRACT
Objectives Dietary supplements may ameliorate SARS- 
CoV-2 infection, although scientific evidence to support 
such a role is lacking. We investigated whether users of 
the COVID-19 Symptom Study app who regularly took 
dietary supplements were less likely to test positive for 
SARS- CoV-2 infection.
Design App- based community survey.
Setting 445 850 subscribers of an app that was launched 
to enable self- reported information related to SARS- CoV-2 
infection for use in the general population in the UK 
(n=372 720), the USA (n=45 757) and Sweden (n=27 373).
Main exposure Self- reported regular dietary supplement 
usage (constant use during previous 3 months) in the first 
waves of the pandemic up to 31 July 2020.
Main outcome measures SARS- CoV-2 infection 
confirmed by viral RNA reverse transcriptase PCR test or 
serology test before 31 July 2020.
Results In 372 720 UK participants (175 652 supplement 
users and 197 068 non- users), those taking probiotics, 
omega-3 fatty acids, multivitamins or vitamin D had a 
lower risk of SARS- CoV-2 infection by 14% (95% CI (8% 
to 19%)), 12% (95% CI (8% to 16%)), 13% (95% CI (10% 
to 16%)) and 9% (95% CI (6% to 12%)), respectively, 
after adjusting for potential confounders. No effect 
was observed for those taking vitamin C, zinc or garlic 
supplements. On stratification by sex, age and body mass 
index (BMI), the protective associations in individuals 
taking probiotics, omega-3 fatty acids, multivitamins and 
vitamin D were observed in females across all ages and 
BMI groups, but were not seen in men. The same overall 
pattern of association was observed in both the US and 
Swedish cohorts.
Conclusion In women, we observed a modest but 
significant association between use of probiotics, omega-3 
fatty acid, multivitamin or vitamin D supplements and 
lower risk of testing positive for SARS- CoV-2. We found no 
clear benefits for men nor any effect of vitamin C, garlic or 
zinc. Randomised controlled trials are required to confirm 
these observational findings before any therapeutic 
recommendations can be made.
INTRODUCTION
A number of micronutrients, including vita-
mins C and D and zinc, have been shown to 
play key roles in supporting immune func-
tion1 2 and in reducing risk of respiratory 
infection.2 3 These nutrients can be obtained 
from the diet and are available as dietary 
supplements either alone or as part of multi-
vitamin or multinutrient mixtures. There are 
many other dietary supplements available 
including, omega-3 fatty acids (‘fish oil’), 
probiotics and plant isolates like garlic.4 The 
use of specific dietary supplements in both 
prevention and acute treatment of infection 
with SARS- CoV-2 has been promoted by prom-
inent medical entertainment personalities on 
television and social media since the begin-
ning of the current coronavirus pandemic.5 
The UK supplement market increased by 
19.5% in the period leading up to the national 
‘lockdown’ in early March 2020,6 with a 110% 
rise in sales of vitamin C and a 93% rise in 
sales of multivitamin supplements.6 Likewise, 
zinc supplement sales increased by 415% 
over the 7- day period ending 8 March, at the 
height of COVID-19 concern in the USA.5
A biologically plausible role exists for 
certain vitamins and minerals in immune 
pathways.1 For example, vitamin D has been 
suggested to reduce SARS- CoV-2 transmis-
sion by enhancing antiviral immunity and to 
reduce mortality by mitigating the cytokine 
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storm linked with severe COVID-19.7 8 Moreover, zinc also 
supports the function of the immune system9 and may 
have specific antiviral effects.10 However, robust evidence 
to support a role for vitamins and minerals in preventing 
infection with SARS- CoV-2 is not available.11 Any such 
evidence would need to take into account factors such 
as socioeconomic status, ethnicity and occupational 
exposure to the virus as well as the requirement of a large 
sample size and a clear confirmation of infection.
By using data from the COVID-19 Symptom Study 
app,12 we tested the hypothesis that individuals taking 
dietary supplements, were at lower risk of testing positive 
for SARS- CoV-2, during the first wave of the pandemic. 
We initially examined whether supplement use was associ-
ated with SARS- CoV-2 infection among 372 720 UK partic-
ipants who reported having been tested for SARS- CoV-2 
using a reverse transcriptase- PCR (RT- PCR) or serology- 
based test. Next, we used data from 45 757 US and 27 373 
Swedish (SE) app users who also reported tests for 
SARS- CoV-2 infection to replicate UK findings.
METHODS
Study setting and participants
The COVID-19 Symptom Study app was developed by 
health data company Zoe Global with input from King’s 
College London, the Massachusetts General Hospital, 
Lund University, Sweden and Uppsala University, Sweden. 
In the UK, it was launched in English on Tuesday the 
24 March 2020; in the USA in English and Spanish on 
Sunday the 29 March 2020 and in Sweden it was launched 
in Swedish on 29 April 2020 as previously described.12 13 
Anyone over 18 years is able to sign up without any restric-
tion. Individuals are also permitted to record information 
for dependencies under the age of 18. Here, we included 
individuals above 16 years of age (online supplemental 
figure S1). The app enabled self- reported information 
related to SARS- CoV-2 infection to be captured. On first 
use, the app recorded self- reported location, age and 
core health risk factors. With continued use, participants 
provided daily updates on symptoms, healthcare visits, 
SARS- CoV-2 test results and if they were self- quarantining 
or seeking healthcare, including the level of interven-
tion and related outcomes. Individuals without apparent 
symptoms were also encouraged to use the app. Through 
direct updates, new or modified questions were added 
in real- time to capture data to test emerging hypotheses 
about COVID-19 symptoms and treatments. Here, we 
analysed data from the 31 July 2020 data dump.
Assessment of exposure
Starting on the 2 June 2020, in the three countries, via the 
app, users were retrospectively asked if they had been taking 
supplements regularly (defined as: >3 times a week for at 
least 3 months) (online supplemental figure S1). Each user 
was able to fill in the supplements questionnaire only once 
(see online supplemental table S1 for list of questions). The 
questionnaire included use of probiotics, garlic, omega-3 
fatty acids (‘fish oils’), multivitamins, vitamin D, vitamin C 
or zinc or no intake of any supplement. Supplement use was 
recorded as yes/no. For all the analyses, the control group 
consisted of individuals not taking any supplement.
Ascertainment of outcomes
Participants were asked if they had been tested for COVID-19 
using a RT- PCR or serology- based test and the results (none, 
negative, pending or positive). Our primary outcome was a 
report of a positive COVID-19 test between the time when 
they first reported on the COVID-19 Symptom Study app and 
31 July 2020. Participants without a positive or negative test 
result were excluded (online supplemental figure S1).
Ascertainment of covariates
Covariates including age, sex, body mass index (BMI), 
smoking, ethnicity, healthcare worker status and presence 
of comorbidities (ie, cancer, diabetes, eczema, heart disease, 
lung disease, kidney disease and hay fever) were self- reported 
via the app. The app also facilitated the index of multiple 
deprivation (IMD) to be generated from the relevant govern-
ment websites of the UK,14 Scotland15 and Wales,16 with the 
most recent IMD available at the time of analysis used. The 
IMD was then categorised into quintiles within- population, 
where 1 is the least deprived and 5 is the most deprived. A 
subset of the UK app users (n=234 271) also completed a 
second retrospective questionnaire investigating diet quality 
at two time points. Here, we included data from the ‘peri- 
pandemic’ time point described as the previous month (from 
user access). The questionnaire included the validated Leeds 
Short Form Food Frequency Questionnaire (FFQ) developed 
by Cleghorn and collaborators and listed in the Nutritools ( 
www. nutritools. org) library.17 18 We computed the validated 
Diet Quality Index, as previously described.18 Briefly, the Diet 
Quality Index was composed of fruit, vegetable, oily fish, fat 
and non- milk extrinsic sugar intakes reflecting five dietary 
components recognised as indicators of a healthy diet. Stan-
dard portion sizes were assigned to each food item on the 
FFQ.18
Data sharing
Anonymised research data are shared with third parties via 
the centre for Health Data Research UK ( HDRUK. ac. uk). 
US investigators are encouraged to coordinate data requests 
through the COronavirus Pandemic Epidemiology Consor-
tium ( www. monganinstitute. org/ cope- consortium). Data 
updates can be found on https://covid.joinzoe.comhttps:// 
covid. joinzoe. com.
Statistical analysis
We studied 372 720 UK app users (aged 16–90 years) who self- 
reported information regarding regular dietary supplement 
usage and outcome of a COVID-19 test. Of these, 23 521 
individuals tested positive for SARS- CoV-2 and 349 199 tested 
negative. Multivariate logistic regression adjusting for age, 
sex, BMI and health status at sign- up was applied to inves-
tigate the association between supplement use and testing 
positive for SARS- CoV-2. We then repeated the analyses (i) 
adjusting for age, sex, BMI, comorbidities (including type 
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2 diabetes, cancer, asthma, heart disease, eczema, hay fever, 
kidney disease and lung disease), IMD, smoking, ethnicity, 
health worker/carer status and diet quality and (ii) stratifying 
by sex, age group (<40, 40–60, >60 years) and BMI categories 
(normal weight, overweight, obese/morbidly obese).
Replication was conducted in two independent datasets 
including 45 757 US and 27 373 SE app users .
All p values presented were two- sided, with statistical signif-
icance determined by the Bonferroni- corrected threshold 
of significance (p=0.05/7=0.007). Statistical analysis was 
performed using Stata V.12 and ExeTera, a Python library 
developed at KCL to clean and process the raw dataset.19
Patient and public involvement
No patients were directly involved in designing the 
research question or in conducting the research. No 
patients were asked for advice on interpretation or writing 
up the results. There are no plans to involve patients 
or relevant patient community in dissemination at this 
moment.
RESULTS
The demographic characteristics of the study population 
are presented in table 1. Briefly, our discovery cohort 
included 372 720 UK app users who reported having had 
an RT- PCR- based or serology test for SARS- CoV-2 and 
who completed the app- based dietary supplement ques-
tionnaire. The study sample was predominantly female 
(66.8%) and >50% were overweight (BMI (SD)=26.8 
(5.6) kg/m2).
As shown in table 1, out of the 372 720 UK app users, 
175 652 (47%) self- reported using supplements regularly 
since the beginning of the pandemic, while 197 068 self- 
reported they were not taking any supplement. This is in 
line with the UK general population supplement usage 
as reported in the National Diet and Nutrition Survey.4 20
In the UK cohort, users regularly supplementing their 
diet (i) with multivitamins had a lower risk of testing posi-
tive for SARS- CoV-2 by 13% (OR (95% CI)=0.87 (0.84 to 
0.90), p=1.62×10−14), (ii) with vitamin D had a lower risk by 
Table 1 Demographic characteristics of the study population
UK (n=372 720) USA (n=45 757) SE (n=27 373)
Supplement users Supplement users Supplement users
Yes No Yes No Yes No
N (%) 175 652 (47.1%) 197 068 (52.9%) 32 314 (70.6%) 13 443 (29.4%) 13 422 (49%) 13 951 (51%)
SARS- CoV-2 positive, n (%) 10 508 (6%) 13 013 (6.6%) 2002 (6.2%) 1211 (9%) 1806 (13.5%) 2206 (15.8%)
Females, n (%) 123 462 (70.3%) 125 651 (63.8%) 22 817 (70.6%) 8210 (61.1%) 9694 (72.2%) 9088 (65.1%)
White, n (%) 163 479 (93.1%) 188 030 (95.4%) 28 143 (87.1%) 11 757 (87.5%) 13 411 (99.9%) 13 943 (99.9%)
Current smoker, n (%) 6004 (3.4%) 10 773 (5.5%) 1252 (3.9%) 924 (6.9%) 735 (5.5%) 795 (5.7%)
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age, years 49.57 (14.2) 46.26 (14.4) 56.24 (15.2) 47.8 (16.0) 49.0 (13.0) 46.63 (12.9)
BMI, kg/m2 26.59 (5.6) 27.04 (5.7) 27.27 (5.9) 27.21 (6) 26.1 (4.8) 26 (4.7)
IMD, median (IQR) 7 (5) 6 (5) – – – –
DQI, median (IQR) 11 (3) 11 (3) – – – –
N (%) N (%) N (%) N (%) N (%) N (%)
Omega-3 39 263 (22.4%) – 8663 (26.8%) – 3039 (22.6%) –
Probiotics 20 449 (11.6%) – 7268 (22.5%) – 1715 (12.8%) –
Garlic 7235 (4.1%) – 1137 (3.5%) – 941 (7%) –
Multivitamins 77 034 (43.9%) – 18 843 (58.3%) – 5496 (41%) –
Vitamin D 86 190 (49.1%) – 19 444 (60.2%) – 6722 (50.1%) –
Vitamin C 46 755 (26.6%) – 10 136 (31.4%) – 4045 (30.1%) –
Zinc 21 776 (12.4%) – 4330 (13.4%) – 2394 (17.8%) –
Type 2 diabetes 5047 (2.9%) 4842 (2.5%) 1787 (5.5%) 437 (3.3%) 331 (2.5%%) 251 (1.8%%)
Cancer 2178 (1.2%) 1902 (1%) 977 (3%) 217 (1.6%) 157 (1.2%) 130 (0.9%)
Asthma 27 146 (15.5%) 26 020 (13.2%) 5015 (15.5%) 1788 (13.3%) 2039 (15.2%) 1673 (12%)
Heart disease 5708 (3.3%) 5278 (2.7%) 2388 (7.4%) 590 (4.4%) 654 (4.9%) 592 (4.2%)
Eczema 22 896 (13%) 23 454 (11.9%) 3423 (10.6%) 1346 (10%) 1768 (13.2%) 1779 (12.8%)
Hay fever 79 024 (45%) 80 114 (40.7%) 17 000 (52.6%) 6256 (46.5%) 5497 (41%) 5256 (37.7%)
Kidney disease 1702 (1%) 1542 (0.8%) 630 (2%) 143 (1.1%) 117 (0.9%) 102 (0.7%)
Lung disease 24 651 (14%) 22 924 (11.6%) 4331 (13.4%) 1329 (9.9%) 1894 (14.1%) 1488 (10.1%)
Self- reported comorbidities were not asked at sign- up and therefore not reported by all subjects.
BMI, body mass index; DQI, Diet Quality Score; IMD, index of multiple deprivation; SE, Sweden.
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9% (OR (95% CI)=0.91 (0.88 to 0.94), p=2.07×10−8); (iii) 
with probiotics had a lower risk by 14% OR (95% CI)=0.86 
(0.81 to 0.92), p=1.99×10−6) and (iv) with omega-3 fatty 
acids had a lower risk by 12% (OR (95% CI)=0.88 (0.84 
to 0.92), p=5.8×10−8), after adjusting for age, sex, BMI, 
sign- up health status and multiple testing (figure 1). 
There were no significant associations in those supple-
menting with zinc, vitamin C or garlic (figure 1). Crude 
results are presented in online supplemental table S2. To 
account for a potential healthy user bias, we did a sensi-
tivity analysis further adjusting for ethnicity, comorbidi-
ties, smoking, IMD and health worker/carer status, results 
remained consistent with the previous analysis (figure 1), 
although the effect of probiotics appeared weaker. We 
also adjusted for the Diet Quality Index. In line with the 
literature,21 we found diet quality and supplements usage 
to be positively correlated (r=0.07, p<0.0001), supporting 
that people whose diet are closer to the recommended 
one are more likely to take supplements compared 
with those whose diet is far from the recommendation. 
However, when we adjust for diet quality, results remain 
consistent, suggesting that the effect of supplement use 
is independent from the effect of diet quality (figure 1).
Next, we ran the analyses stratifying by sex, age group 
and BMI categories and we detected sexual dimorphism 
in the association between supplement use and testing 
positive for SARS- CoV-2 (figure 1). Females taking probi-
otics, omega-3 fatty acids, multivitamins and vitamin D 
had a lower risk of infection across all age groups and 
BMI categories (OR (95% CI) ranging from 0.73 (0.63 to 
0.85) for probiotics in women <40 years of age to 0.91 
(0.86 to 0.96) for vitamin D in women aged between 40 
and 60 years). No protective association was observed in 
males overall. However, in post hoc subgroup analyses, 
men aged <40 years or normal weight and taking multi-
vitamins and men aged 40–60 years and taking omega-3 
fatty acids were less likely to be infected (figure 1). In 
contrast, there was a positive association in men aged 
>60 years taking zinc (1.4 (1.16 to1.69), p=4.92×10−4) or 
vitamin C supplements (1.22 (1.05 to 1.41), p=8.1×10−3) 
(figure 1) for testing positive for SARS- CoV-2.
To replicate significant findings from the UK cohort, 
we next used data from the 45 757 US and 27 373 SE 
app users. Cohorts were similar, in that they were also 
predominantly female (USA: 67.8%, SE: 68.6%) and a 
greater proportion were overweight (BMI (SD), USA: 
27.3 (5.9) kg/m2, SE: 26 (4.7) kg/m2). Overall UK find-
ings were mirrored in both cohorts (figure 2). However, 
findings by gender varied different in different cohorts 
(figure 2).
Associations in females were replicated in the US 
cohort, but omega-3 supplement use was not associated 
with testing positive in Swedish females (figure 2). US 
males using probiotics or vitamin D had a decreased 
risk of a positive test for SARS- CoV-2 (figure 2), while 
Swedish men taking probiotics, omega-3 fatty acids, 
multivitamins or vitamin D had a decreased risk of infec-
tion (figure 2).
Figure 1 Associations between testing positive for SARS- CoV-2 and self- reported use of supplements in UK app users. 
Each cell of the matrix displays the OR of the association between use of a type of supplement and testing positive with the 
corresponding p value in parentheses. The table is colour coded according to the OR, with blue denoting a reduced risk and red 
denoting an increased risk of testing positive. Bold entries are statistically significant after accounting for multiple testing using 
Bonferroni correction. Dem, adjusted for age, sex, body mass ndex (BMI) and health status at sign up; All, adjusted for Dem, 
index of multiple deprivation, ethnicity, comorbidities (type 2 diabetes, cancer, asthma, heart disease, eczema, hay fever, kidney 
disease and lung disease), smoking, diet quality; stratified analyses are adjusted for age, (BMI) and health status at sign up as 
appropriate.
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DISCUSSION
In the largest observational study on SARS- CoV-2 infection 
and dietary supplement use to date on over 400 000 app 
users from three different countries, we show a significant 
association between users of omega-3 fatty acid, probi-
otic, multivitamin or vitamin D supplements and lower 
risk of testing positive for infection with SARS- CoV-2. 
However, our stratified analysis in the tested group shows 
a strong sexual dimorphism with the consistent protective 
effect present only in females, at least in the UK, and for 
some supplements in the USA and SE. This association 
has several potential explanations including: (i) biolog-
ical explanations include discordant immune systems 
between sexes that could respond differently to supple-
ments.22 Indeed, a sexual dimorphism in nutrient metab-
olism has been previously reported, with females having 
a more robust immune response than men.23 Moreover, 
females typically possess a more resilient immune system 
than males with higher numbers of circulating B cells 
when matched for age, BMI and clinical parameters,24 as 
well as a slower age- related decline in circulating T cells 
and B cells.24 It is therefore plausible that supplements 
could better support the immune system of females than 
males, although the lack of consistency between coun-
tries is problematic; (ii) differences in body weight and 
body composition between males and females meaning 
that supplement dosing on a per body weight basis may 
be higher in females25; (iii) residual confounding due to 
sex differences in health- related behaviours, including 
COVID-19.26 Polling reveals that a greater percentage of 
females versus males are anxious for the health of them-
selves or their family and therefore are more precau-
tionary, cancelling plans and staying home more often.26 
Females who purchase vitamins may also be more health 
conscious than males, such as having greater use of 
wearing face masks and hand- washing.27–29 Indeed, in our 
data, we found that women tended to wear masks more 
often than males (44% of women report wearing a mask 
at least some of the time when outside, compared with 
36% of men, p<0.001).
Vitamin D
A potential antimicrobial role of vitamin D in infections 
dates back almost a century,30 with several mechanistic 
study supporting a positive physiological role.3 Immune 
cells express the vitamin D receptor and some can synthe-
sise the active form of vitamin D. Vitamin D influences 
the function of antigen- presenting cells, T cells and B 
cells.31 It also promotes production of cathelicidin, a 
microbicidal component of the innate immune system.32 
The overlap between risk factors for vitamin D deficiency 
and risk of severe COVID-19, such as obesity, age and 
ethnicity, gives some plausibility to a protective role of 
vitamin D.30 A meta- analysis of 39 randomised controlled 
trials reported that vitamin D reduces the risk of respira-
tory infections by around 11%, but there was considerable 
heterogeneity.33 However, a Mendelian randomisation 
study suggests that genetic levels of vitamin D are not 
associated with COVID-19 susceptibility,34 in line with 
recent results from the UKBiobank.35
Figure 2 ORs and 95% CIs for the associations between testing positive for SARS- CoV-2 and self- reported use of 
supplements in three cohorts (n=372 720 UK, n=45 575 USA and n=27 373 SE). Overall sample analyses are adjusted for age, 
sex, body mass index (BMI) and health status at sign up. Analyses according to sex are adjusted for age, BMI and health status 
at sign up.
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In our data, we find a modest protective effect for infec-
tion, with a 9% reduction in risk of testing positive for 
SARS- CoV-2 in the overall UK cohort, 24% in the US 
cohort and 19% in the SE group.
Multivitamins
Multivitamin supplements typically include multiple vita-
mins and multiple minerals including trace elements36; 
many of these have antioxidant properties and roles in 
supporting the immune system.1 2 Specific micronutrient 
deficiencies, including zinc, selenium, vitamin A, vitamin 
D and vitamin E, have been shown to be detrimental 
during viral infections.37–39 Although some randomised 
controlled trials have shown that multivitamin supple-
ments reduce the risk of respiratory infections,40 a recent 
review argues that this evidence is weak and unclear.41 
Here, we provide evidence to support a modest protective 
effect in those taking multivitamin supplements similar to 
vitamin D with a 13% reduction in risk of testing positive 
for SARS- CoV-2 in the overall UK cohort, 12% in the US 
cohort and 22% in the SE cohort.
Omega-3 fatty acids
Omega-3 fatty acids can influence antigen- presenting cell, 
T- cell and B- cell function, although their effects on these 
cell types in humans is not consistently reported. However, 
they are clearly demonstrated to be anti- inflammatory42 
and to be converted to specialised proresolving media-
tors such as resolvins, protectins and maresins.43 Whether 
this is a mechanism by which they reduce risk of testing 
positive for SARS- CoV-2 is not clear. Nevertheless, here we 
provide evidence to support a protective effect in omega-3 
fatty acid supplements users with a 12% reduction in 
risk of testing positive for SARS- CoV-2 in the overall UK 
cohort, 21% in the US cohort and 16% in the SE cohort. 
Although, in the UK, stratified analysis shows this effect 
is largely driven by females, and only significant in one 
male stratum.
Probiotics
Probiotics modify the host’s gut microbiota and may 
generate antiviral metabolites, and they interact with the 
host’s gut- associated immune system.44 This can result 
in improved immunity, including enhanced responses 
to the seasonal influenza vaccine.45 Mechanistic studies 
support a gut- lung axis,46 whereby immune effects of 
microbiota at the gut level can be transferred to the 
lung, most likely through movement of immune cells. 
This could explain why some probiotic organisms reduce 
risk47–49 and severity50 of respiratory tract infections. 
Here, we provide evidence to suggest that people taking 
probiotics supplements are modestly protected with a 
14% reduction in risk of testing positive for SARS- CoV-2 
in the overall UK cohort, 18% in the US cohort and 37% 
in the SE cohort. However, effects of probiotics are strain 
and species specific and we have no information of which 
probiotics or their quality were being used by partici-
pants in this study. Moreover, when we adjusted for other 
covariates including diet, the effect of probiotics was 
weaker suggesting that probiotic use may be confounded 
by a healthy diet.
Zinc, vitamin C and garlic
We saw no protective effects of zinc, garlic or vitamin C. Both 
zinc and vitamin C have been previously suggested to support 
the immune system and to prevent respiratory infections.1 2 51 
Although, their efficacy and evidence base has been ques-
tioned and a meta- analysis of vitamin C showed no preventive 
benefit but a reduction in severity and a modest reduction in 
symptom duration.52 53
Strengths of our study include its large sample size, the 
confirmation of SARS- CoV-2 through a RT- PCR- based or 
serology- based test, and the replication of the key findings 
from the UK cohort in two other cohorts, one in the US 
cohort and the other in SE cohort. Furthermore, we had 
information on diet quality. Indeed, consistent with the liter-
ature,21 in our data we found a positive correlation between 
diet quality and supplements usage suggesting that people 
with a healthier diet were more likely to take supplements. 
However, we were able to adjust for diet quality and showed 
that the effect of supplements is independent from the effect 
of diet quality.
Our study also has a number of limitations. First, we used 
self- reported data which can introduce information bias, 
including misclassification, or effect bias exposure if partici-
pants started taking supplements after developing symptoms. 
There is also a possibility of participants having COVID-19 
symptoms (and likely having COVID-19) but not having had 
any test because of low testing capacity54 and then started 
taking supplements. We believe this is possible, although 
would have reduced any real effect. To help mitigate poten-
tial spurious associations, we adjusted for self- reported health 
status at sign- up. Second, participants using the app were 
a self- selected group and may not be fully representative 
of the general population. Indeed, our study population is 
predominantly female, although supplement usage and 
BMI are in line with data for the UK general population.4 20 
This may cause collider bias, that is, both use of supplements 
and having COVID-19 might influence the probability of an 
individual participating in the COVID-19 Symptom Study, 
and this selection effect could introduce an apparent asso-
ciation between supplement use and COVID-19 status.55 
Third, the SARS- CoV-2 infection diagnosis was mainly based 
on the RT- PCR test that has <100% sensitivity (true positive 
rate).56 57 Fourth, participants might have been taking supple-
ments in addition to the seven we asked them about, and we 
were not able to account for multiple sources of vitamins/
minerals. Fifth, malnutrition is a significant risk factor for a 
severe form of COVID-19 infection,58 however we had infor-
mation on diet, we were unable to infer vitamin/mineral 
deficiencies. Sixth, we do not know the exact intakes of the 
ingredients within the supplements used by the participants, 
nor we had any information regarding dosage and hence 
we were unable to link supplements dosage or intakes from 
multiple sources with disease outcome. Furthermore, within 
the useful timeframe, the app has not captured information 
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on behaviours such as washing hands, use of disinfectants 
or social distancing and only a proportion of participants 
replied to the questions on use of masks. We also were only 
able to adjust for a crude, area- based, measure of deprivation 
rather than individually based measures of socioeconomic 
background, such as educational attainment, occupation and 
income; thus, residual confounding by socioeconomic status 
is possible. Finally, this is observational data captured during 
a specific timeframe, and our study design does not allow an 
inference of causality.
In conclusion, our data show that women taking multivi-
tamins, omega-3 fatty acids, vitamin D or probiotics have a 
slightly lower risk of SARS- CoV-2 infection in the UK, US 
and SE cohorts, but no effect in those taking zinc, vitamin 
C or garlic. Given the interest in supplements during the 
pandemic, large randomised controlled trials of selected 
supplements testing their protective effects, and also possible 
adverse effects, on disease severity are required before any 
evidence- based recommendations can be made. We eagerly 
await the result of ongoing trials, including of vitamin D, 
omega-3 fatty acids and probiotics and COVID-19 risk.59
What this paper adds
What is already known on this topic
 ► Dietary supplements have been shown to play key roles in support-
ing immune function, but the extent to which specific supplements 
are associated with reduced risk of SARS- CoV-2 infection is not 
known.
What this study adds
 ► Individuals taking multivitamins, omega-3 fatty acids, probiotics or 
vitamin D were less likely to be tested positive for SARS- CoV-2 in 
three large independent cohorts of app users.
 ► There was a significant protective association for vitamin D, ome-
ga-3 fatty acids, probiotics and multivitamins in female users across 
all ages and body mass index categories within the largest (UK) co-
hort; yet, there was no association in male users of this cohort.
 ► Vitamin C, zinc and garlic supplements had no association with risk 
for SARS- CoV-2.
 ► There is a need for randomised controlled trials of selected 
supplements.
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